Calycosin mitigates chondrocyte inflammation and apoptosis by inhibiting the PI3K/AKT and NF-ΚB pathways

Ethnopharmacological relevance: Shaoyao Gancao Decoction (SG-Tang), originated from the Treatise on Febrile Diseases, is often used to treat OA pain symptoms. Whereas its efficacy has been verified by several clinical studies, the underlying mechanism remained unclear. Network pharmacology and UPLC-QTOF-MS analysis found that calycosin could be regarded as the active components of SG-Tang in treating OA. However, the effect of calycosin on cartilage destruction and the pathogenesis of OA are not known. Therefore, we evaluated the benefits of calycosin for OA and revealed the underlying mechanisms.Aim of study: Using network pharmacology, UPLC-QTOF-MS analysis and experiments, the active components of SG-Tang were analyzed to explore their potential therapeutic mechanism in OA.Materials and methods: The components of SG-Tang were detected by UPLC-QTOF-MS, and the possible active components and mechanism of SG-Tang in the treatment of OA were screened by network pharmacology. The OA mouse model was constructed by DMM. In total, 30 mice were randomly divided into three groups: Sham, DMM, and DMM + Calycosin. H&E, safranin O/fast green staining and the OARSI scores were used to evaluate joint injury in mice. In addition, OA models were established using chondrocytes treated with 10 ng/mL IL-1 beta. Treatment groups were treated with 100, 200 or 400 mu M calycosin. CCK-8 assay was used for assessing the cytotoxic effects of calycosin. TUNEL staining and Western blotting were used to detect chondrocyte apoptosis. In addition, PI3K/Akt and NF-Kappa B signaling pathway-related markers and cartilage matrix-related indicators were also detected.Results: In vivo studies showed that calycosin inhibited IL-1 beta-induced IL-6 and TNF-alpha production, as well as iNOS and COX-2 expression. Meanwhile, calycosin could inhibit IL-1 beta-induced degradation of cartilage matrix, including downregulation of MMP3, MMP-13, collagen II and aggrecan. NF-Kappa B and PI3K/AKT were also inhibited by calycosin in OA chondrocytes. Furthermore, calycosin inhibited IL-1 beta-induced apoptosis in mouse chon-drocytes. In a mouse model of OA, our results suggest that calycosin has a chondroprotective effect. Conclusions: According to this study, calycosin may act as a protective agent against OA by inhibiting the PI3K/ AKT and NF-Kappa B pathways. Furthermore, this study suggested that calycosin is a potential candidate for the treatment of OA.